Skip to main content
Journal cover image

Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.

Publication ,  Journal Article
Gastman, B; Agarwal, PK; Berger, A; Boland, G; Broderick, S; Butterfield, LH; Byrd, D; Fecci, PE; Ferris, RL; Fong, Y; Goff, SL; Grabowski, MM ...
Published in: J Immunother Cancer
November 2020

Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarkers. The success of biomarker development is dependent on accurate and timely collection of biospecimens and high-quality processing, storage and shipping. Tumors are also increasingly used as source material for the generation of therapeutic T cells. There have been few guidelines or consensus statements on how to optimally collect and manage biospecimens and source material being used for immunotherapy and related research. The Society for Immunotherapy of Cancer Surgery Committee has brought together surgical experts from multiple subspecialty disciplines to identify best practices and to provide consensus on how best to access and manage specific tissues for immuno-oncology treatments and clinical investigation. In addition, the committee recommends early integration of surgeons and other interventional physicians with expertise in biospecimen collection, especially in clinical trials, to optimize the quality of tissue and the validity of correlative clinical studies in cancer immunotherapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

November 2020

Volume

8

Issue

2

Location

England

Related Subject Headings

  • Tissue and Organ Procurement
  • Medical Oncology
  • Immunotherapy
  • Humans
  • Clinical Trials as Topic
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gastman, B., Agarwal, P. K., Berger, A., Boland, G., Broderick, S., Butterfield, L. H., … Kaufman, H. L. (2020). Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer, 8(2). https://doi.org/10.1136/jitc-2020-001583
Gastman, Brian, Piyush K. Agarwal, Adam Berger, Genevieve Boland, Stephen Broderick, Lisa H. Butterfield, David Byrd, et al. “Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.J Immunother Cancer 8, no. 2 (November 2020). https://doi.org/10.1136/jitc-2020-001583.
Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, et al. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 2020 Nov;8(2).
Gastman, Brian, et al. “Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.J Immunother Cancer, vol. 8, no. 2, Nov. 2020. Pubmed, doi:10.1136/jitc-2020-001583.
Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 2020 Nov;8(2).
Journal cover image

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

November 2020

Volume

8

Issue

2

Location

England

Related Subject Headings

  • Tissue and Organ Procurement
  • Medical Oncology
  • Immunotherapy
  • Humans
  • Clinical Trials as Topic
  • 3211 Oncology and carcinogenesis
  • 3204 Immunology